Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock

  • HC Wainwright initiated coverage of Lyell Immunopharma Inc LYEL with a Buy rating and a price target of $12 per share
  • Lyell leverages two ex vivo epigenetic reprogramming technologies, Gen-R and Epi-R, which are designed to generate T-cell populations that are more effective and resilient. 
  • The analyst believes the technologies position Lyell as a solid tumor cell therapy leader.
  • LYL845 is a tumor-infiltrating lymphocyte (TIL) therapy designed to incorporate the Epi-R technology. 
  • HC Wainwright says LYL845 design can potentially help overcome challenges associated with competing TIL products, including limited efficacy due to poor enrichment of tumor-reactive T cells, poor quality and growth potential of expanded T cells, and failure to maintain polyclonality of TILs during production. 
  • Earlier this month, the FDA cleared the Investigational New Drug application to initiate a Phase 1 trial for LYL845. 
  • Patient screening for the Phase 1 trial is set to begin over the coming months, and initial clinical data is expected in 2024.
  • Price Action: LYEL shares are up 3.98% at $6.80 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!